Medical solution company Boston Scientific Corporation (NYSE:BSX) disclosed on Tuesday the completion of the acquisition of Vertiflex Inc for USD465m in an upfront cash deal.
In addition, Boston will announce additional payments contingent on commercial milestones for the next three years.
Vertiflex Inc is a privately-held company that developed and commercialised the Superion Indirect Decompression System, a minimally-invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS) – the narrowing of the spinal canal, which can cause compression of nearby nerves.
Upon closing, the acquisition of Vertiflex adds the only US FDA-approved, commercially-available, minimally-invasive interspinous spacer to Boston's industry-leading pain management portfolio of spinal cord stimulation and radiofrequency ablation.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT